1. Home
  2. ALKS vs CRSP Comparison

ALKS vs CRSP Comparison

Compare ALKS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkermes plc

ALKS

Alkermes plc

HOLD

Current Price

$38.99

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$53.28

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKS
CRSP
Founded
1987
2013
Country
Ireland
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.9B
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
ALKS
CRSP
Price
$38.99
$53.28
Analyst Decision
Buy
Buy
Analyst Count
14
17
Target Price
$43.43
$70.29
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,475,899,000.00
$289,590,000.00
Revenue This Year
$24.26
$807.72
Revenue Next Year
$4.47
$172.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$25.17
$34.87
52 Week High
$38.45
$78.48

Technical Indicators

Market Signals
Indicator
ALKS
CRSP
Relative Strength Index (RSI) 71.82 50.38
Support Level $27.65 $50.74
Resistance Level N/A $60.45
Average True Range (ATR) 1.29 2.88
MACD 0.34 -0.07
Stochastic Oscillator 87.89 54.10

Price Performance

Historical Comparison
ALKS
CRSP

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: